J
Javier P. Gisbert
Researcher at Autonomous University of Madrid
Publications - 1076
Citations - 39753
Javier P. Gisbert is an academic researcher from Autonomous University of Madrid. The author has contributed to research in topics: Helicobacter pylori & Inflammatory bowel disease. The author has an hindex of 95, co-authored 990 publications receiving 33726 citations. Previous affiliations of Javier P. Gisbert include Services Hospital & University of Alcalá.
Papers
More filters
Journal ArticleDOI
Microbiota sensing by mincle-syk axis in dendritic cells regulates interleukin-17 and -22 production and promotes intestinal barrier integrity
María Martínez-López,Salvador Iborra,Salvador Iborra,Ruth Conde-Garrosa,Annalaura Mastrangelo,Camille Danne,Elizabeth R. Mann,Elizabeth R. Mann,Delyth M. Reid,Valérie Gaboriau-Routhiau,María Chaparro,María M. Lorenzo,Lara Minnerup,Paula Saz-Leal,Emma Slack,Benjamin Kemp,Javier P. Gisbert,Andrzej Dzionek,Matthew J. Robinson,Francisco J. Rupérez,Nadine Cerf-Bensussan,Nadine Cerf-Bensussan,Gordon D. Brown,David Bernardo,Salomé LeibundGut-Landmann,David Sancho +25 more
TL;DR: Host signaling pathways linking recognition of commensal microbes and Th17 differentiation are explored, finding that the Mincle‐Syk axis in Peyer's patch DCs detects mucosal‐resident bacteria, inducing IL‐6 and IL‐23p19 and stimulating IL‐17 andIL‐22 production by intestinal T cells and ILCs, which control the intestinal immune barrier function.
Journal ArticleDOI
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
TL;DR: Triple therapies combining a double dose of proton pump inhibitor plus two antibiotics are the standard treatment for Helicobacter pylori infection, but some reports suggest that the use of half the dose of Proton Pump inhibitor is equally effective.
Journal ArticleDOI
Systematic review with meta‐analysis: inflammatory bowel disease in the elderly
Javier P. Gisbert,María Chaparro +1 more
TL;DR: Elderly patients represent an increasing proportion of the inflammatory bowel disease (IBD) population and the number of older patients diagnosed with IBD is expected to increase in the coming years.
Journal ArticleDOI
Clinical trial: clarithromycin vs. levofloxacin in first‐line triple and sequential regimens for Helicobacter pylori eradication
Javier Molina-Infante,Belen Perez-Gallardo,Miguel Fernández-Bermejo,Moises Hernandez-Alonso,G. Vinagre,C. Dueñas,Jose M. Mateos-Rodriguez,G. Gonzalez-Garcia,Elena Garcia Abadia,Javier P. Gisbert +9 more
TL;DR: In this paper, the authors compared clarithromycin and levofloxacin in triple and sequential first-line regimens for Helicobacter pylori eradication.
Journal ArticleDOI
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
María Chaparro,A. Verreth,Triana Lobatón,E. Gravito-Soares,Mette Julsgaard,Edoardo Savarino,Fernando Magro,I. Avni Biron,P. Lopez-Serrano,María José Casanova,M. Gompertz,S. Vitor,M. Arroyo,Daniela Pugliese,Y. Zabana,R. Vicente,M. Aguas,A Bar-Gil Shitrit,A. Gutierrez,Glen A. Doherty,L. Fernandez-Salazar,J. Martinez Cadilla,J. Huguet,Aoibhlinn O'Toole,E. Stasi,N. Mancenido Marcos,Albert Villoria,K. Karmiris,Jean-François Rahier,C. Rodriguez,M. Diz-Lois Palomares,Gionata Fiorino,J. Benitez,Mariabeatrice Principi,Timna Naftali,Carlos Taxonera,Gerassimos J. Mantzaris,L. Sebkova,B. Iade,D. Lissner,I. Ferrer Bradley,A. Lopez-San Roman,I. Marin-Jimenez,O. Merino,M. Sierra,M. Van Domselaar,Flavio Caprioli,I. Guerra,P. Peixe,M. Piqueras,I. Rodriguez-Lago,Y. Ber,K van Hoeve,P. Torres,M Gravito-Soares,D Rudbeck-Resdal,O. Bartolo,A. Peixoto,G. Martin,Alessandro Armuzzi,A. Garre,Maria G. Donday,F J Martín de Carpi,Javier P. Gisbert +63 more
TL;DR: In utero exposure to anti-TNFα drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.